Jackson Center, PA, December 17, 2020 – Halberd Corp. (OTC PINK: "HALB") announced they are pursuing development of their latest extracorporeal treatment variation in the fight against COVID-19. Halberd’s provisional patent application, “Method For Treating And Curing Covid-19 Infection By Utilizing Radio Frequency Extracorporeally To Eradicate The Virus,” was filed last month. The procedure is ...
Jackson Center, PA, December 14, 2020 – Halberd Corporation (OTC PINK: "HALB") announced its proprietary, highly potent, neutralizing antibody against SARS-CoV-2, which demonstrated very strong receptor specificity and inhibition of SARS-CoV-2 replication. Halberd’s anti-Spike protein monoclonal antibody, recently filed with the United States Patent Office, underwent in vitro studies at Arizona State University (ASU). Based ...
Jackson Center, PA, December 7, 2020 – Halberd Corporation (OTC PINK: "HALB") announced the promising results of laboratory testing on their new patent pending SARS-COV-2 monoclonal antibody generated through their university research. The antibody testing to date has shown extremely potent action against the SARS-CoV-2 spike protein. Scientific details of the testing to date will ...
Jackson Center, PA, December 2, 2020 – Halberd Corp. (OTC PINK: "HALB") was recently included in a Momentum Observer article on Covid-19 along with big pharma companies Pfizer (PFE: NYSE), Moderna (MRNA: NASDAQ), BioNTech (BNTX: NASDAQ) and AstraZeneca (AZN: NASDAQ). The article featured Halberd's nasal spray currently under development that could be an effective alternative ...
Jackson Center, PA, December 1, 2020 – Halberd Corp. (OTC PINK: "HALB") announces the reorganization of its Scientific Advisory Board. The new Advisory Board will consist of two sub-boards: a multi-disciplined Scientific Advisory Board focused on biomedical issues and a Business Advisory Board focusing on business issues. The two boards will interface on a regular ...
Jackson Center, PA, November 19, 2020 – Halberd Corp. (OTC PINK: "HALB") reported the filing of a provisional patent application on a variation of Halberd’s patented extracorporeal method to treat/eradicate Covid-19 from a patient’s blood. By using an extracorporeal (outside the body) treatment method, the patient is exposed to far fewer potential negative side effects ...
Jackson Center, PA, November 12, 2020 – Halberd Corporation (OTC PINK: "HALB") today disclosed information on their patent-pending fluorescent anti-Spike protein monoclonal antibodies against Covid-19 developed in conjunction with Dr. Qiang (Shawn) Chen of Arizona State University. The salient feature of Halberd’s new class of antibody is that it fluoresces in the presence of Covid-19 ...
Jackson Center, PA, October 27, 2020 – Halberd Corporation (OTC PINK: "HALB") has retained the services of a prestigious Pittsburgh, PA law firm, Ference & Associates, to handle its intellectual property matters. The initial application focuses on patenting Halberd’s base Covid-19 antibody as well as an entire new class of antibody conjugate. The primary attorney ...
In Case You Missed It Phoenix, Arizona–(Newsfile Corp. – October 22, 2020) – The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB) (“the Company”), a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. CEO of the Company, Bill Hartman, joined Stock Day host Everett Jolly. ...
Updated 12:30PM Jackson Center, PA, October 19, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced the creation of a new class of anti-Spike protein monoclonal antibodies against Covid-19. The discovery is the result of Halberd’s research in conjunction with Arizona State University’s Dr. Qiang “Shawn” Chen, utilizing Halberd’s intellectual property created by Mitchel S. ...